Matthias Pfisterer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthias Pfisterer has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Christoph Kaiser
10 shared publicationsPeter Rickenbacher
7 shared publicationsPeter Buser
5 shared publicationsStefan Osswald
5 shared publicationsHans Peter Brunner-La Rocca
Department of Cardiology , University Hospital Basel , Petersgraben 4, CH-4031 Basel , Switzerland
4 shared publicationsPaul Erne
4 shared publications
Latest Publications
- Open Access
- 16 February 2014
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 35 (17) , 1098-1100
Drug-eluting stents with biodegradable polymers: are enough data in for a final assessment?
This editorial refers to ‘Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis’†, by S.-H. Kang et al., on page 1147
- 16 February 2014
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 35 (17) , 1098-1100
Open AccessDrug-eluting stents with biodegradable polymers: are enough data in for a final assessment?
This editorial refers to ‘Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis’†, by S.-H. Kang et al., on page 1147
- Open Access
- 5 December 2012
- Published by Springer Nature
Trial of Invasive versus Medical therapy of Early coronary artery disease in Diabetes Mellitus
- 5 December 2012
- Published by Springer Nature
Open AccessTrial of Invasive versus Medical therapy of Early coronary artery disease in Diabetes Mellitus
- 1 December 2011
- Published by Wolters Kluwer Health in Circulation
No One-Size-Fits-All
- 22 August 2009
- Vol. 139, 481-5
Detection of intake of nonsteroidal anti-inflammatory drugs in elderly patients with heart failure. How to ask the patient?
Heart failure hospitalisations may be related to non-steroidal anti-inflammatory drug (NSAID) use. Since NSAIDs are usually prescribed by general practitioners or taken without prescription, their use may be largely underestimated. Therefore, we assessed the impact of a focussed analgesic medication history as compared to a usual medication history on detection of NSAID intake in elderly heart failure patients and the potential effect of medical advice on discontinuation of this therapy in a non-controlled study design. A structured and stepwise history of analgesic intake (firstly open questioning about medication intake, secondly with a focus on analgesic intake, finally focussing on behaviour in case of pain) was done in 197 elderly heart failure patients taking part in the TIME-CHF study at baseline and up to 3 follow-up visits. All participants were informed about the potential hazardous effects of NSAIDs and alternative analgesic therapy was proposed in case of NSAID intake. Patients were aged 60 years or older with clinical signs of heart failure NYHA > or =II, elevated NT-BNP, and had been hospitalised due to heart failure within the last year. Details of this study have been described previously. At baseline, 43 patients (22%) were taking NSAID. Almost half (n = 19) taking NSAID reported the use only after specific questioning. Therefore, a focussed analgesic medication history was superior as compared to a usual medication history to detect patients taking NSAIDs (22% vs 12%; p <0.001). After instruction and proposal of alternative analgesic therapy, NSAID intake dropped from 22% to 7% (p <0.001). No risk factor for continuous use was identified. NSAID use in heart failure patients is relatively common. Specific questioning may help to increase detection of NSAID intake and information on its hazardous effects to decrease NSAID use.
- 22 August 2009
- Vol. 139, 481-5
Detection of intake of nonsteroidal anti-inflammatory drugs in elderly patients with heart failure. How to ask the patient?
Heart failure hospitalisations may be related to non-steroidal anti-inflammatory drug (NSAID) use. Since NSAIDs are usually prescribed by general practitioners or taken without prescription, their use may be largely underestimated. Therefore, we assessed the impact of a focussed analgesic medication history as compared to a usual medication history on detection of NSAID intake in elderly heart failure patients and the potential effect of medical advice on discontinuation of this therapy in a non-controlled study design. A structured and stepwise history of analgesic intake (firstly open questioning about medication intake, secondly with a focus on analgesic intake, finally focussing on behaviour in case of pain) was done in 197 elderly heart failure patients taking part in the TIME-CHF study at baseline and up to 3 follow-up visits. All participants were informed about the potential hazardous effects of NSAIDs and alternative analgesic therapy was proposed in case of NSAID intake. Patients were aged 60 years or older with clinical signs of heart failure NYHA > or =II, elevated NT-BNP, and had been hospitalised due to heart failure within the last year. Details of this study have been described previously. At baseline, 43 patients (22%) were taking NSAID. Almost half (n = 19) taking NSAID reported the use only after specific questioning. Therefore, a focussed analgesic medication history was superior as compared to a usual medication history to detect patients taking NSAIDs (22% vs 12%; p <0.001). After instruction and proposal of alternative analgesic therapy, NSAID intake dropped from 22% to 7% (p <0.001). No risk factor for continuous use was identified. NSAID use in heart failure patients is relatively common. Specific questioning may help to increase detection of NSAID intake and information on its hazardous effects to decrease NSAID use.
- Top Cited Papers
- 28 January 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 301 (4) , 383-392
BNP-Guided vs Symptom-Guided Heart Failure Therapy
Research from JAMA — BNP-Guided vs Symptom-Guided Heart Failure Therapy — The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial
- 28 January 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 301 (4) , 383-392
Top Cited PapersBNP-Guided vs Symptom-Guided Heart Failure Therapy
Research from JAMA — BNP-Guided vs Symptom-Guided Heart Failure Therapy — The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial
- 9 September 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 118 (11) , 1117-1119
Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction
- 9 September 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 118 (11) , 1117-1119
Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction
Improvements in physical and mental domains of quality of life by anti-ischaemic drug and revascularisation treatment in elderly men and women with chronic angina
Background: The severity of angina is related to a reduction in global quality of life (QoL), which may be improved by anti-ischaemic treatment. It is not known, however, whether improvements relate only to physical or also to mental and social domains of QoL and whether women benefit in a similar way to men. Objectives: To relate improvements in angina severity through anti-ischaemic treatment to physical and mental domains of QoL in elderly men and women and to assess differences in this relation between the sexes. Methods: Angina severity and full assessment of QoL by structured, self-administered and validated questionnaires were measured prospectively at baseline and after 6 months’ optimal drug or revascularisation treatment in all 301 patients of the Trial of Invasive versus Medical therapy in Elderly (TIME) patients with chronic angina. Results: At baseline, angina severity correlated significantly with physical domains of QoL (trend test at least pConclusions: These findings confirm the relation between angina severity and physical limitation. In addition, they show that anti-ischaemic treatment not only relieves angina and improves physical components of QoL but also improves mental and social domains. This is true for women as well as for men despite the lower overall scores for women.
Improvements in physical and mental domains of quality of life by anti-ischaemic drug and revascularisation treatment in elderly men and women with chronic angina
Background: The severity of angina is related to a reduction in global quality of life (QoL), which may be improved by anti-ischaemic treatment. It is not known, however, whether improvements relate only to physical or also to mental and social domains of QoL and whether women benefit in a similar way to men. Objectives: To relate improvements in angina severity through anti-ischaemic treatment to physical and mental domains of QoL in elderly men and women and to assess differences in this relation between the sexes. Methods: Angina severity and full assessment of QoL by structured, self-administered and validated questionnaires were measured prospectively at baseline and after 6 months’ optimal drug or revascularisation treatment in all 301 patients of the Trial of Invasive versus Medical therapy in Elderly (TIME) patients with chronic angina. Results: At baseline, angina severity correlated significantly with physical domains of QoL (trend test at least pConclusions: These findings confirm the relation between angina severity and physical limitation. In addition, they show that anti-ischaemic treatment not only relieves angina and improves physical components of QoL but also improves mental and social domains. This is true for women as well as for men despite the lower overall scores for women.
- Open Access
- 28 July 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (1) , 16-24
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
To assess the long-term benefit–risk ratio of drug-eluting (DES) vs. bare-metal stents (BMS) relative to stent size. All 826 consecutive BASKET (BAsel Stent Kosten-Effektivitäts Trial) patients randomized 2:1 to DES vs. BMS were followed after 3 years. Data were analysed separately for patients with small stents (n = 268) vs. only large stents (≥3.0 mm native vessels, n = 558). Clinical events were related to stent thrombosis. Three-year clinical target-vessel revascularization rates remained borderline reduced after DES [9.9 vs. 13.9% (BMS), P = 0.07], particularly in patients with small stents (10.7 vs. 19.8%, P = 0.03; large stents: 9.5 vs. 11.5%, P = 0.44). Cardiac death/myocardial infarction (MI) rates (12.7 vs. 10.0%, P = 0.30) were similar, however, death/MI beyond 6 months was higher after DES [9.1 vs. 3.8% (BMS), P = 0.009], mainly due to increased late death/MI in patients with large stents (9.7 vs. 3.1%, P = 0.006). The results paralleled findings for stent thrombosis. The clinical benefit of DES was maintained at no overall increased risk of death or death/MI up to 3 years. However, death/MI rates were increased in DES vs. BMS patients beyond 6 months, particularly in patients with large stents, paralleling findings for stent thrombosis. Thus, stent size seems to influence the 3-year benefit–risk ratio after DES implantation.
- 28 July 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (1) , 16-24
Open AccessLong-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
To assess the long-term benefit–risk ratio of drug-eluting (DES) vs. bare-metal stents (BMS) relative to stent size. All 826 consecutive BASKET (BAsel Stent Kosten-Effektivitäts Trial) patients randomized 2:1 to DES vs. BMS were followed after 3 years. Data were analysed separately for patients with small stents (n = 268) vs. only large stents (≥3.0 mm native vessels, n = 558). Clinical events were related to stent thrombosis. Three-year clinical target-vessel revascularization rates remained borderline reduced after DES [9.9 vs. 13.9% (BMS), P = 0.07], particularly in patients with small stents (10.7 vs. 19.8%, P = 0.03; large stents: 9.5 vs. 11.5%, P = 0.44). Cardiac death/myocardial infarction (MI) rates (12.7 vs. 10.0%, P = 0.30) were similar, however, death/MI beyond 6 months was higher after DES [9.1 vs. 3.8% (BMS), P = 0.009], mainly due to increased late death/MI in patients with large stents (9.7 vs. 3.1%, P = 0.006). The results paralleled findings for stent thrombosis. The clinical benefit of DES was maintained at no overall increased risk of death or death/MI up to 3 years. However, death/MI rates were increased in DES vs. BMS patients beyond 6 months, particularly in patients with large stents, paralleling findings for stent thrombosis. Thus, stent size seems to influence the 3-year benefit–risk ratio after DES implantation.